Since NAFLD seems to be associated with classical indicators of metabolic syndrome (e.g., insulin resistance, Type 2 diabetes, and dyslipidemia), it is no wonder that LCN2 overexpression was lately defined as a hepatic manifestation of a metabolic syndrome [28]. The gene discussed is LCN2; the disease is Insulin resistance.